Phase IIa Study of the Efficacy of Single Agent BGJ398 (Infigratinib) in FGFR1-3 Translocated, Mutated, or Amplified Squamous Cell Carcinoma of the Head and Neck
Phase of Trial: Phase II
Latest Information Update: 12 Jun 2018
At a glance
- Drugs Infigratinib (Primary)
- Indications Head and neck cancer; Squamous cell cancer
- Focus Therapeutic Use
- 05 Jun 2018 Planned number of patients changed from 30 to 20.
- 05 Jun 2018 Planned End Date changed from 1 Jul 2020 to 1 Jun 2025.
- 05 Jun 2018 Planned primary completion date changed from 1 Jul 2020 to 1 Jun 2025.